T-Cell Lymphoma Neuropathy Differs From B-Cell Counterpart, Often Neurolymphomatosis

Navigating Neuropathic Complications in T-Cell Lymphomas

Peripheral neuropathies are a known complication in hematologic malignancies, but their presentation in T-cell lymphoproliferative disorders has remained particularly obscure [1, 2]. T-cell lymphomas are often aggressive, and their associated neurological syndromes can pose significant diagnostic and therapeutic challenges for clinicians [3, 4]. While general guidelines exist for managing immune-related neurological events in oncology, they often do not address the specific mechanisms of neuropathy arising directly from the malignancy itself [5, 6]. A recent multicenter study now provides needed clarity on the distinct clinical and pathological features of these rare but severe neuropathies, offering a framework for improved clinical assessment.

Unraveling a Rare and Complex Neuropathy

Peripheral neuropathies (PNs) associated with T-cell lymphoproliferative disorders (T-Ly) are exceptionally rare and have been poorly characterized, creating a significant knowledge gap for practicing physicians. It has been unclear whether their underlying mechanisms, clinical features, and patient outcomes differ from the more frequently studied PNs associated with B-cell lymphoproliferative disorders (B-Ly). To address this, investigators launched a comprehensive study to define the clinical, electrophysiologic, and pathologic spectrum of T-Ly-associated PN. A primary goal was to evaluate treatment responses and directly compare the findings against a reference cohort of patients with B-Ly-associated PN to identify any distinguishing characteristics.

Study Design and Patient Cohort Characteristics

To amass a sufficient sample of this rare condition, researchers conducted a retrospective multicentric cohort study, pooling data from 17 specialized peripheral neuropathy reference centers in France and Switzerland. The study included 50 adult patients with a confirmed diagnosis of both PN and T-Ly, after carefully excluding cases where neuropathy could be attributed to other causes or where disease was confined to the central nervous system. A multidisciplinary consensus process classified each PN case as either neurolymphomatosis (direct nerve infiltration) or dysimmune neuropathy. Functional outcomes were measured using the modified Rankin Scale (mRS) for overall disability and the Overall Neuropathy Limitations Scale for neuropathy-specific deficits. The T-Ly cohort had a median age of 66 years and was 60% male. The most common T-Ly subtype was peripheral T-cell lymphoma, not otherwise specified (38%), followed by angioimmunoblastic T-cell lymphoma (28%). Notably, PN onset was synchronous with the T-Ly diagnosis in 40% of patients, preceded it in 20%, and occurred after diagnosis in 40%. The median overall survival from the onset of neuropathy was a stark 24 months.

Distinct Clinical and Pathological Profiles Emerge

The investigation provided a clearer understanding of the pathophysiology driving these neuropathies. The authors determined that the primary mechanism was neurolymphomatosis, a direct infiltration of peripheral nerves by malignant lymphoma cells, which was diagnosed in 50% of cases. A substantial subset of patients (35%) had a dysimmune neuropathy, which is an indirect, immune-mediated attack on the nervous system often considered a paraneoplastic phenomenon. When compared to a reference cohort with B-cell lymphoma-associated PN, the T-Ly group showed a dramatically different mechanistic profile. Neurolymphomatosis was the cause in 50% of T-Ly cases versus only 10% in B-Ly cases (P = 0.014). This fundamental difference in pathology likely explains the more severe clinical picture observed in the T-Ly cohort, which included more frequent and severe motor involvement, a higher incidence of pain, and more common cranial nerve involvement. These findings suggest that neuropathy in T-Ly is more often a direct, destructive consequence of the cancer itself.

Clinical Implications and Future Directions

This study's results have immediate clinical relevance for physicians managing patients with T-cell lymphomas. The data strongly indicate that T-Ly-associated PN is a distinct clinical entity, not simply a variant of what is seen in B-cell malignancies. The key takeaway is that these neuropathies are predominantly driven by direct nerve infiltration (neurolymphomatosis), leading to more severe clinical profiles and poorer neurologic outcomes compared to B-Ly-associated PN. This high prevalence of an infiltrative mechanism should raise a clinician's index of suspicion and may warrant a more aggressive diagnostic workup, such as nerve biopsy, to confirm the diagnosis. At the same time, the finding that dysimmune neuropathies represent a substantial subset, particularly in patients with angioimmunoblastic T-cell lymphoma, highlights that a single diagnostic approach does not fit all cases. Although the study is limited by its retrospective design and the heterogeneity of investigations across centers, its findings underscore the need for early recognition and the development of mechanism-specific therapeutic strategies to improve outcomes in this challenging patient population.

References

1. Bird JM, Owen RG, D’Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology. 2011. doi:10.1111/j.1365-2141.2011.08573.x

2. Terpos E, Kleber M, Engelhardt M, et al. European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica. 2015. doi:10.3324/haematol.2014.117176

3. Horwitz SM, Ansell SM, Ai WZ, et al. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2022. doi:10.6004/jnccn.2022.0015

4. Cervantes‐Villagrana RD, Albores‐García D, Cervantes-Villagrana AR, García-Acevez SJ. Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduction and Targeted Therapy. 2020. doi:10.1038/s41392-020-0205-z

5. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology. 2021. doi:10.1200/jco.21.01440

6. Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Review of Pathology Mechanisms of Disease. 2020. doi:10.1146/annurev-pathol-042020-042741